Ronald Paraham

Ronald Paraham supports the FDA Office of Acquisition and Grant Services in executing strategic procurement activities critical to advancing regulatory science and public health infrastructure. Though his formal title is not listed, his role centers on managing complex acquisitions for scientific and technical services that underpin the FDA’s mission to ensure the safety and efficacy of medical products. He routinely handles procurements for research support, analytical instrumentation maintenance, and specialized consulting services essential to laboratory operations and regulatory decision-making, ensuring alignment with federal acquisition regulations and agency scientific priorities. His contracting patterns reflect deep engagement with niche scientific vendors, particularly TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLC, TOXICOLOGIC PATHOLOGY ASSOCIATES INC, and PROGENICS PHARMACEUTICALS INC, indicating a focus on high-specialization contractors offering clinical research support, toxicological analysis, and pharmaceutical development services. These partnerships suggest a preference for vendors with domain expertise in regulatory science, drug safety evaluation, and biomedical research, often requiring rigorous compliance with Good Laboratory Practices and FDA submission standards. Paraham’s procurement portfolio shows no use of socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a strategic emphasis on technical capability over socioeconomic criteria, prioritizing subject-matter expertise and proven performance in highly specialized domains where only a limited pool of qualified vendors exists. His primary NAICS focus—513210 (Software Publishers), 541720 (Research and Development in the Social Sciences and Humanities), and 541990 (All Other Professional, Scientific, and Technical Services)—underscores a reliance on computational modeling, behavioral and policy research, and bespoke scientific consulting. He procures services that integrate data analytics, regulatory impact assessment, and laboratory support systems, demonstrating expertise in bridging technical innovation with regulatory compliance in pharmaceutical and biomedical research environments.